BOSTON, Massachusetts, April 28 -- The Institute for Clinical and Economic Review issued the following announcement: The Institute for Clinical and Economic Review (ICER) released an Evidence Report assessing the comparative clinical effectiveness and value of elexacaftor/tezacaftor/ivacaftor (Trikafta(R), Vertex Pharmaceuticals) for the treatment of cystic fibrosis (CF). ICER also examined new data that have become available since its May 2018 review of three related CF treatments: ivacaftor (  more

HOUSTON, Texas, April 28 -- The University of Texas's MD Anderson Cancer Center issued the following news release on April 27: New data from the Phase III EMBRACA trial led by researchers at The University of Texas MD Anderson Cancer Center found the PARP inhibitor talazoparib did not demonstrate a statistically significant overall survival (OS) benefit for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes. Most patients included in the study went on to rec  more